ANTHERA PHARMACEUTICALS INC

As of March 31, 2018, ANTHERA PHARMACEUTICALS INC carries a market capitalization of 8.36M, placing it among publicly traded companies globally. Its enterprise value stands at 275,669.06, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2018, ANTHERA PHARMACEUTICALS INC has 26.18M shares outstanding.

These figures are as of March 31, 2018.

As of March 31, 2018, ANTHERA PHARMACEUTICALS INC maintains a current ratio of 3.30, meaning it holds 3.3x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended March 31, 2018, ANTHERA PHARMACEUTICALS INC posted a negative return on equity (ROE) of -635.43, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -144.38, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 27.00, a quick read on workforce productivity versus industry peers.

As of the close on October 8, 2026, ANTHERA PHARMACEUTICALS INC's stock has declined approximately 86.50% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.

Over the twelve months ended March 31, 2018, ANTHERA PHARMACEUTICALS INC generated - - in revenue and converted that into -23.39M in net income, yielding earnings per share of -1.66. EBITDA reached -36.40M, while operating income came in at -36.70M.

These figures are as of March 31, 2018. Total book value stands at 5.46M, with working capital of 6.09M providing operational flexibility.

ANTHERA PHARMACEUTICALS INC produced -31.95M in operating cash flow over the twelve months ended March 31, 2018. After subtracting - - in capital expenditures, free cash flow totaled -31.95M - equivalent to -2.26 per share.

These figures cover the twelve months ended March 31, 2018. The dividend payout ratio of 6.18 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -708.97: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -227.56, meaning ANTHERA PHARMACEUTICALS INC raised more capital through share issuance and new debt than it returned via dividends and buybacks.

ANTHERA PHARMACEUTICALS INC's most recent stock split took place on May 1, 2017 with a 8:1 split ratio.

As of March 31, 2018, ANTHERA PHARMACEUTICALS INC has an Altman Z-Score of -81.67, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.